Member Info for TrickyEFC

New shy how ya been the last 6 years 😜

Ha ha 5 million seller back. Jesus has he not learnt yet.

And ps mms doing it again. NT on sells to make people panick in a NT sells.

Don't fall for it if you believe

Again are we

Vinyl the mms could be working a large order.

Can sell just shy 24.5 for over 13 mill

Https://www.singercm.com/appointment-as-corporate-broker-of-solvonis-therapeutics-plc/

The 2.5mil and now 5mil sells don't seem to be stopping the rise

It does aklee. Half Fridays volume done now

Anthony has alluded to licensing before. Think it's his ideal option

Of a quarter of Fridays done in 30mins.

Licensing deals happen more than take overs.

😁

Good luck with 9.30

😜

Anyone wanting a large amount of these

200 million volume on friday and to shine the spotlight some more on that late buy it equated to 10% of the days volume.

if people wish to facilitate any more trades of similar size this week then don't **** ya pants ladies and gentlemen while it rockets.

more eyes and bigger buys while we await the next bit of news will be more than enough to shift it

Https://x.com/SerialInvestor8/status/1933897485639975406

been posted few times here but good link for any new eyes

A 10 increase will get us sat valued at around £125mill valuation before a big offer comes in.

Chas had a brain malfunction then was about to say can't see the chairman selling any but forgot for a moment he ain't the chairman no more

Graft Polymer PLC Information

There is currently no data for GPL

Directorate Change and grant of options

26 Sep 2024 07:00

RNS Number : 6777F

Graft Polymer (UK) PLC

26 September 2024

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION WILL BE CONSIDERED TO BE IN THE PUBLIC DOMAIN.

26 September 2024

Graft Polymer (UK) Plc(the "Company")

Appointment of biotechnology industry leader Dennis Purcell as Chairman

and grant of options

Graft Polymer (UK) PLC (LON: GPL), an innovative biotechnology company focused on co-developing therapeutics for mental health disorders, is pleased to announce the appointment of Dennis Purcell to the Company's Board as Chairman. Mr Purcell replaces Nicholas Nelson as Chairman, who remains on the Board as a Non-Executive Director.

A pioneer in the biotechnology industry, Mr Purcell is the Founder and former Senior Managing Partner of Aisling Capital LLC ("Aisling Capital"), a leading U.S. healthcare investment firm which has raised $1.8 billion since its inception. Prior to founding Aisling Capital, Mr Purcell served as Managing Director of the Healthcare Investment Banking Group at Hambrecht & Quist (later part of JP Morgan), where he led over $20 billion in financing for the pharmaceutical, biotechnology and medical device sectors of the healthcare industry.

Mr Purcell has extensive experience in helping biotechnology companies access the capital markets, along with deep involvement in mergers, acquisitions, and strategic partnerships. His leadership has been instrumental in the success of numerous early-stage companies. As Graft Polymer continues to advance its co-development of therapeutics for mental health disorders, Mr. Purcell's knowledge and global network will be invaluable in expanding the Company's presence in both U.S. and European markets.

Question re the management shares at 0.6p

Can anyone expand on what this means?

Nicholas Nelson (Non-Executive Chairman) and William Potts, a consultant to the Company (together the "Lenders") have provided a £200,000 working capital loan facility to the Company (the "Loan Facility"), details of which were announced on 15 March 2024 and 23 April 2024. The Loan Facility has been drawn in full and it has been agreed by the Lenders that repayment of the principal amount and all interest accrued will be satisfied by the issue of 132,000,000 new Ordinary Shares (the "Loan Conversion Shares") to each of the Lenders. Each Lender will also receive warrants over 132,000,000 new Ordinary Shares, exercisable at 0.1 pence per Ordinary Share for a period of three years from Admission (as defined below).

Further to a conditional fundraising by the Company announced on 22 December 2023, a total of 59,666,667 new Ordinary Shares (the "Management Shares") are to be issued at a price of 0.6 pence per Management Share (as set out below) in satisfaction of liabilities owed by the Company to those individuals: